Oncology Articles | Page 3

CLL Expert Explains Latest Treatment Developments in the Field
Neil E. Kay, MD, discusses the available options and sequencing challenges for patients with relapsed/refractory chronic lymphocytic leukemia, as well as next steps for advancing outcomes for this patient population.
FDA Approves Brentuximab Vedotin for Frontline Hodgkin Lymphoma
The FDA has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma.
Klopp Comments on Optimizing Chemoradiation in Endometrial Cancer
Ann H. Klopp, MD, PhD, discusses optimizing the use of chemoradiation and the future of the treatment landscape in endometrial cancer.
Expert Shares Excitement Over Biosimilars in Oncology
Sunil Verma, MD, shares his insight on the approval of MYL-1401O, as well as his excitement for the future development of biosimilars across oncology.
Atezolizumab Plus Chemo Improves PFS in Frontline Squamous NSCLC
The addition of atezolizumab to frontline carboplatin and nab-paclitaxel delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer.
FDA Grants Enzalutamide Priority Review for Nonmetastatic CRPC
The FDA has granted a priority review to a supplemental new drug application (sNDA) for enzalutamide (Xtandi) for the treatment of men with nonmetastatic castration-resistant prostate cancer.
CMS to Cover Genomic Testing for Patients With Cancer
The Centers for Medicare & Medicaid Services has announced that it will cover diagnostic laboratory tests using Next Generation Sequencing for patients with advanced cancer.
Optimizing HER2-Targeted Therapy
Sara Hurvitz, MD, and Sunil Verma, MD, share their expert insight on the latest groundbreaking developments in HER2-positive breast cancer.
Atezolizumab, Cobimetinib Combo Active in mCRC
Atezolizumab in combination with cobimetinib induced a 31% disease control rate in patients with heavily-pretreated metastatic colorectal cancer.
No Benefit With Postoperative Chemoradiotherapy Versus RT Alone in HNSCC
The addition of weekly carboplatin following surgery and radiation therapy did not improve freedom from locoregional relapse in patients with high-risk cutaneous head and neck squamous cell carcinoma.
Publication Bottom Border
Border Publication